57 results about "Hematologic disease" patented technology

The invention belongs to the technical field of medical treatment, and discloses a blood product virus inactivation system based on a synergistic effect of nano-catalysis photochemical inactivation and low-temperature plasma, the system comprises: a nano-photocatalysis inactivation module adopting titanium dioxide TiO2 and graphite phase carbon nitride g-C3N4 nano-materials as photocatalysts; the low-temperature plasma inactivation module adopts a low-temperature plasma generator to generate plasma cloud above the blood product and release active particles; the dynamic fluid stirring module is used for enabling the blood product to uniformly receive photocatalysis and plasma inactivation effects through a microfluid mixing technology so as to ensure the uniformity of virus inactivation; the sensing monitoring and intelligent feedback module is used for monitoring the residual quantity of viral nucleic acid and the activity of protein in the blood in real time by adopting a spectrum sensor and a biochemical sensor. The method can be widely applied to the fields of clinical blood transfusion, blood product manufacturing, blood disease treatment and the like, promotes the progress of a blood safety guarantee technology, reduces the virus infection risk and improves the patient safety.

The invention relates to the technical field of medical information systems, in particular to a blood smear abnormal cell intelligent recognition system and method based on deep learning. The multi-stage convolutional neural network module is in data connection with the image acquisition module, and the abnormal cell bank module is in data connection with the multi-stage convolutional neural network module; the knowledge graph module is in data connection with the abnormal cell bank module, and the blood index calculation module is in data connection with the multistage convolutional neural network module and the abnormal cell bank module and is used for calculating various blood indexes; generating a graphical display result of the blood indexes; the result output module is in data connection with the knowledge graph module and the blood index calculation module; according to the blood disease diagnosis method and system, the whole process from image acquisition to diagnosis report generation can be automatically completed, detailed analysis results and diagnosis suggestions can be provided for doctors, and the efficiency and accuracy of blood disease diagnosis are greatly improved.

The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease or neurodevelopmental disease), inflammatory or autoimmune disease, infection, metabolic disease, hematologic disease, or cardiovascular disease.

The invention relates to the technical field of medical informatization, and particularly discloses a blood disease intelligent diagnosis and treatment data processing system which adopts an image processing technology based on deep learning to perform cell detection on a bone marrow morphological image of a patient object so as to focus on a cell target in the image. The method comprises the following steps: acquiring a cell target, performing multi-level feature extraction on the cell target to capture superficial detail features and trunk features of the cell, and performing significant sparse interactive coding on the superficial detail features and the trunk features to obtain cell feature representation with higher distinction degree, thereby realizing intelligent identification of abnormal cells. Through the mode, the cell characteristics in the blood sample can be automatically identified and analyzed, and rapid detection and diagnosis of abnormal cells are realized, so that a doctor can be assisted to carry out faster and more accurate blood disease diagnosis, and the workload of the doctor is relieved.

The invention discloses a KMT2A fusion gene detection primer probe group, a kit and a detection method, the primer probe group is specifically designed based on KMT2A gene fusion and 13 common partner genes MLLT3, AFF1, MLLT10, MLLT1, MLLT4, ELL, EPS15, SEPT6, MLLT11, MLLT6, SEPT9, AFF3 and CBL fusion sites, the mutual interference is small, the primer probe group can be used for targeted amplification of a fusion gene specific region in a single-tube mixed solution, the detection sensitivity is high, the detection time is short, the detection time is short, and the detection efficiency is high. According to the present invention, the rapid detection of any one fusion gene type in 67 types can be achieved, and compared with the high-throughput sequencing, the sensitivity is high, the detection rate is high, the single sample detection cost is low, the method is suitable for the clinical auxiliary diagnosis of the large batch of samples, and the guidance is provided for the diagnosis, the treatment and the prognosis of the blood disease patients.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention discloses a blood pathology image analysis system based on artificial intelligence, and relates to the technical field of pathology image analysis, the blood pathology image analysis system comprises a pathology image database module, a sample experiment module, a pathology analysis module, a similar pathology retrieval module, a treatment course segmentation module, a medicine medical analysis module and a stage medical module, the system has the advantages that pathological images can be searched and classified more quickly through the pathological image database module, reference and comparison are provided for analyzing new pathological samples, image information with the highest similarity can be retrieved through the similar pathological retrieval module, and treatment data are extracted to generate treatment course information; the treatment experience of similar cases can be quickly referred, the medicine medical analysis module is beneficial to reasonably selecting medicines and evaluating the medicine treatment effect, the treatment scheme can be dynamically adjusted according to the actual condition of a patient through the stage medical module, the treatment scheme can be adjusted according to different conditions, and the flexibility of the scheme is improved.

The invention relates to the technical field of medical equipment, in particular to a portable diagnosis and treatment instrument for blood disease treatment, which comprises a box body and moving wheels, an opening is formed in the upper end of the box body, locking openings are formed in two sides of the top of the box body, and the moving wheels are mounted on the box body; the partition plate is fixedly mounted in the middle of the box body; the access mechanism is installed on the box body, the control end of the access mechanism is arranged outside the box body, and the power output end of the access mechanism is fixedly connected with diagnosis and treatment equipment; the outward pushing mechanisms are fixedly installed on the two sides of the partition plate, extending mechanisms penetrate through the outward pushing mechanisms on the two sides, and one ends of the extending mechanisms are connected with the diagnosis and treatment equipment; the box cover is matched with the opening of the box body, rotary knobs are rotationally installed on the two sides of the box cover, and clamping plates are fixedly arranged on the rotary knobs; and the handle is fixedly mounted on the box cover. The portable diagnosis and treatment instrument for blood disease treatment provided by the invention not only can diagnose and treat blood diseases, but also has better portability, meanwhile, diagnosis and treatment equipment can be quickly taken out or put into the box body, the operation is simple, and the practicability is high.

The present invention relates to nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and / or prevention of blood disorders, in particular sickle cell disease. The invention also relates to a pharmaceutical composition comprising the compound of formula (I) for use in the treatment and / or prevention of erythrocyte disorders, in particular sickle cell disease.

The invention relates to a sepsis progress risk prediction method and system for a hematological deficiency patient. The method comprises the following steps: controlling a sepsis sequencing platform to perform transcriptome sequencing on peripheral blood to obtain clean gene sequence data; identifying abnormal genome concentration corresponding to sepsis in the clean gene sequence data; and inputting the abnormal genome concentration into the abnormal progress risk prediction model corresponding to sepsis to obtain abnormal progress risk prediction data. By adopting the method, early risk prediction can be realized.

The present invention relates to a nicotinamide mononucleotide derivative of formula (I) which is used for treating and / or preventing blood disorders, especially sickle cell disease. The present invention also relates to a pharmaceutical composition comprising a compound of formula (I) which is used for treating and / or preventing red blood cell disorders, especially sickle cell disease.

In accordance with various embodiments of the present disclosure, a method for non-invasive blood disorder monitoring is provided. In some embodiments, the method comprises emitting light from a photonic integrated circuit-scale dual frequency comb at a plurality of different wavelengths via a hand-held device directed at one or more bodily structures of a patient having been diagnosed with a blood disorder; detecting acoustic waves from thermo-elastic changes in red blood cells within the bodily structures; generating an optical absorption spectrum from the detected acoustic waves; identifying elements within the bodily structures exposed to the emitted light based on the optical absorption spectrum; and generating a three-dimensional image of one or more blood vessels based on the optical absorption spectrum from the detected acoustic waves from the red blood cells to identify a blockage or partial blockage of blood flow in the one or more blood vessels.

The present invention discloses a multi-model fusion classification method based on blood diseases, comprising the following steps: obtaining a data set; dividing the data set into k parts based on a k-fold cross-validation method to obtain a test set and a training set, where k is any constant greater than 1; selecting a plurality of machine learning binary classifier models for data set training; fusing a plurality of machine learning binary classifier models by linear addition to obtain a fused multi-classifier model; using the machine learning multi-classifier model to train a multi-label data set to obtain a model accuracy rate; using the fused multi-classifier model to train a multi-label data set to obtain an accuracy rate of the fused multi-classifier model, and comparing it with the above accuracy rate. The present invention adopts the above-mentioned multi-model fusion classification method based on blood diseases, which can quickly classify blood diseases to help doctors quickly diagnose, reduce doctors' workload, and improve their work efficiency.

The present invention provides a pulse-type blood-drawing device for patients with blood diseases, belonging to the technical field of medical devices. The device comprises a support base, a limiting groove is provided on the top outer wall of the support base, a heating pad is installed on the inner wall of the limiting groove, a first C-shaped buckle is fixedly connected to the top inner wall of the support base, sliding grooves are provided on the outer walls of both sides of the support base, a plurality of latching teeth are fixedly connected to the inner walls of the sliding grooves, and connecting columns are symmetrically fixedly connected to the outer walls of both sides of the support base; a pulse-drawing component is used to promote blood collection after the venous blood filling is apparent. The pulse-drawing component can be set up to inflate a rubber airbag by stepping on a foot pump, thereby compressing the patient's arm vein, making the vein more filled with blood, and facilitating medical personnel to find a suitable vein for puncture. Such a setting can avoid medical personnel from feeling fatigued due to frequent bending or stretching of the arms, as well as the restriction of heavy clothing.

Compositions and methods for treating a blood disorder in a subject comprising delivering a nucleic acid molecule including a nucleotide sequence encoding two to six guide RNAs (gRNAs) into a hematopoietic stem cell (HSC), a hematopoietic progenitor cell (HPC), or a population of hematopoietic stem and progenitor cells (HSPCs) are described.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention discloses a blood disease marrow fluid sample collection device, and belongs to the technical field of medical instruments, the device comprises a collection main body, a first piston assembly, a second piston assembly and a filter assembly, the collection main body is internally provided with a first chamber; the first piston assembly is arranged in the first cavity, the second cavity is formed in a piston rod body of the first piston assembly, the second piston assembly is arranged in the second cavity, and the second cavity and the first cavity are connected through a second cavity communicating channel; the filtering assembly is arranged at the front end of the communicating channel of the second cavity, after the first piston assembly is driven to extract marrow fluid into the first cavity, the collecting body is removed from the puncture needle, and the second piston assembly is driven to suck the marrow fluid in the first cavity into the second cavity; the bone marrow particle tissue in the bone marrow fluid in the first cavity is collected through the filter screen, separated collection of the bone marrow fluid and the bone marrow particles is completed, the complete structure of the bone marrow particles can be guaranteed, and the collection efficiency is higher.

The utility model provides a blood disease chemotherapy patient skin care device which comprises a care device bottom plate, a connecting plate is fixedly arranged on one side of the top end of the care device bottom plate, a control handle is installed at the top end of the connecting plate, the control handle is in an L shape and can be conveniently held by medical staff, and a heat dissipation plate is fixedly arranged at one end of the care device bottom plate. According to the scheme, the medicine spraying plate is controlled to be started by pressing the control button, at the moment, the medicine spraying plate is started, the atomization spray head is turned on and turned off, and nursing liquid medicine in the storage disinfection tank is atomized outwards through the atomization spray head and applied to the positions, where symptoms occur, such as swelling, itching, dryness, desquamation and even ulceration, of the skin surface of a patient; and the skin care work of medical personnel is facilitated.

The invention relates to the field of chemotherapy toxicity prediction modeling, in particular to a construction method of a blood disease chemotherapy toxicity prediction model. According to the method, the dynamic metabolic coefficient of a patient to be detected is obtained according to the change of absolute neutrophil count of the patient to be detected after current chemotherapy and the albumin content and bilirubin level after current chemotherapy, and the injury coefficient of the patient to be detected is obtained according to the medication dosage and toxicity level of the patient to be detected in current chemotherapy. Obtaining a toxicity accumulation coefficient of the patient to be detected in the current chemotherapy by combining the content of the toxicity detection marker before the previous chemotherapy and the drug exposure dose of the current chemotherapy, constructing a bone marrow state vector and a liver state vector, and adjusting the liver state vector to obtain an adjusted liver state vector of the patient to be detected in the current chemotherapy; and constructing a chemotherapy toxicity prediction model by combining the multi-modal data of all patients in all historical chemotherapy periods. According to the method, the accurate chemotherapy toxicity prediction model can be established, and the chemotherapy toxicity prediction deviation is reduced.

The invention provides a blood disease physiological feature extraction method, electronic equipment and a program product. The method comprises the following steps: acquiring an infrared video and a visible light video obtained by shooting the face of a detected user; inputting the infrared image frame into a thermodynamic diagram prediction model subjected to training test to obtain a blood vessel density thermodynamic diagram output by the thermodynamic diagram prediction model; determining a region of interest based on the signal-to-noise ratio of the BVP signal of the face obtained from the visible light image frame; taking the BVP signal in the region of interest as a target BVP signal; and feature extraction and recognition are performed on the target BVP signal by using a multi-task graph convolutional network to obtain an extraction result, and the extraction result comprises physiological features of the tested user and probability distribution of the blood disease corresponding to the physiological features. In this way, the region of interest for extracting the stable BVP signal can be dynamically determined for different users, and the accuracy of extracting the blood disease physiological features from the image can be improved.

The present invention provides a rapid, non-invasive, and antibody-free method for identifying AA and MDS based on Raman spectroscopy. This method utilizes the peak intensity of Raman spectra as a biomarker for the preparation of products for predicting or detecting blood disorders. The specificity and significant Raman shifts of the present invention are valuable biomarkers for early disease identification, improving diagnostic efficiency, reducing testing costs, and promoting the rapid and accurate diagnosis of AA and MDS.

Methods of administering isolated anti-CD38 antibodies at low dosages subcutaneously are disclosed. The methods provide an effective treatment for autoimmune diseases and cancers, including hematologic diseases. Also disclosed are unit dosage forms for the anti-CD38 antibodies.

The present disclosure provides techniques for detecting blood disorders using cell-free DNA in a blood sample, e.g., using plasma or serum. For example, an analysis can target one or more differentially methylated regions specific to a particular blood cell lineage (e.g., erythroblasts). Methylation levels can be quantified from the analysis to determine the amount of methylated or unmethylated DNA fragments in the cell-free mixture of the blood sample. The methylation levels can be compared to one or more cutoff values, e.g., corresponding to a normal range for the particular blood cell lineage, as part of determining a level of a blood disorder.

The present application relates to the technical field of blood extraction, in particular to a cell separation and extraction device for animal blood disease detection, which comprises a box body, a partition plate is arranged at the bottom of the box body, a cavity is formed between the box body and the partition plate, a centrifugal assembly is arranged in the cavity, and the centrifugal assembly is used for placing test tubes for centrifugal operation, the test tubes after centrifugation are taken out and replaced by collection test tubes, the piston rod at the end of the air cylinder drives the rack to reciprocate in the vertical direction, the rack drives the double-head gear rod to mesh and rotate in the moving process, the double-head gear rod drives the second wedge-shaped plate to reciprocate at a 90° angle in the rotating process, so that the second wedge-shaped plate reciprocally extrudes the first wedge-shaped plate, the air in the rubber head of the suction tube is continuously sprayed out, in the process of air spraying to generate airflow, the airflow pushes and extrudes the cell liquid temporarily stored in the glass tube of the suction tube, so that the cell liquid enters the collection test tube for collection, and the accuracy of animal pathological detection is improved.

The application discloses a kind of based on microfluidic and AI image recognition basophil activation detection method and system.The method comprises: the peripheral blood sample to be measured is injected into the microfluidic chip device containing conical microporous filter membrane and enriched basophil;In reaction cavity, pre-mixed dry CD63-FITC and CD203c-PE fluorescently labeled antibody and allergen stimulant are added;After incubation at 37 DEG C, 512×512 pixel high-resolution image is obtained by digital microscopic imaging system;Improved target detection model is used to identify activated cells, the model uses lightweight FasterNet backbone network and dynamic attention mechanism, generates cell activation heat map by Gaussian kernel density estimation, combines fluorescence intensity weighted calculation activation index and outputs visual report.System includes microfluidic chip module, fluorescently labeled module, temperature control incubation module, image acquisition module, AI analysis module and man-machine interaction module.The application realizes high sensitivity, high specificity and automatic detection, and is suitable for clinical diagnosis of allergic diseases and blood diseases.

The invention relates to the technical field of electric digital data processing, in particular to a blood disease medical report processing method. The method comprises the following steps: acquiring a to-be-processed medical report of the blood disease, wherein the to-be-processed medical report comprises information related to associated characteristics of the blood disease; if the medical report of the blood disease to be processed is in a text format, determining the medical report of the blood disease to be processed as a target text; if the medical report of the blood disease to be processed is in a picture format, performing OCR (Optical Character Recognition) on the medical report of the blood disease to be processed, and determining a text obtained after recognition as a target text; inputting the target text into the trained large model, so that the trained large model outputs a tag list X corresponding to the target text; and traversing X, and writing xj into the jth position in the preset template text to obtain a structured text corresponding to the medical report of the blood disease to be processed. According to the invention, the key information can be accurately extracted from the medical report of the blood disease.

According to the blood pathology image analysis method and system based on the adaptive technology provided by the invention, at least two pieces of first blood pathology image information with consistent or similar directories are analyzed to obtain at least one comparison queue; analyzing at least one piece of second blood pathology image information except the at least two pieces of first blood pathology image information in the at least one comparison queue to obtain second blood pathology image information associated with the at least two pieces of first blood pathology image information; therefore, the abnormal points on the image can be accurately determined, the condition of the patient can be obtained, and medical staff can be assisted to quickly treat the patient.

The subject matter disclosed herein relates to a method of treating a Blood Disorder in a subject in need thereof, the method comprising administering to the subject with a Blood Disorder a composition targeting a telomerase in a Giant Cell of the Disorder.

A construction method of a blood disease knowledge graph database is characterized by comprising the following steps: determining a target user and a purpose of the database, and defining a concept and a relationship of a blood disease field; blood disease field data are collected and preprocessed; using a natural language processing technology to extract entities, relationships and attributes in the blood disease data text, and establishing relationships among the entities; establishing a blood disease ontology model and designing a database; storing the processed data in a database, designing query and retrieval interfaces, and supporting a user to query and browse a knowledge graph; and verifying the accuracy and integrity of the knowledge graph. According to the method, through the accurate entities and the relation model, the relation among the entities such as diseases, symptoms and treatment methods in the knowledge graph is clearer. The method is helpful for users to better understand related knowledge of blood diseases, and supports clinical decision and research. An effective updating mechanism is constructed, and it is ensured that information in the knowledge graph is synchronized with the latest medical research progress and clinical practice.